- In vitro and in vivo efficacy studies and preclinical pharmacology
- Various carcinogen-induced and genetically engineered animal models of cancer
- Identification and evaluation of intermediate biomarkers
- PK and PK/PD modeling to evaluate efficacy and optimize dosing regimen
- Characterization of immune responses to vaccines and immunomodulatory agents
- Formulation optimization for enhanced bioavailability and clinical usefulness
- Analytical method development for investigational agents in bulk form and in biological fluids and tissues
- Scale-up cGMP and non-cGMP production of an investigational agent
- Stability testing for bulk and formulated material
- Preclinical investigational new drug (IND)-directed GLP toxicology studies
- Regulatory support
- Other resources to support drug development
View the Prime Contractors 2019-2023 and Animal Models Used by PREVENT.